Q-omics provides the consensus-scored RNA5SP508 profile across patient tissues and cancer cell-line models. RNA5SP508 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNA5SP508 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, RNA5SP508 RNA expression shows 12,089 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, LIHC, and TGCT as cancer lineages where RNA5SP508 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP508 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP508 survival associations across molecular data types. RNA5SP508 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP508 RNA expression–survival associations across cancer types. High RNA5SP508 expression shows unfavorable associations in MESO, UCS, BRCA, OV and LUSC, but favorable associations in LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RNA5SP508 RNA expression.
This table summarizes RNA5SP508 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP508. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP508 shows higher tumor expression in LIHC. The LIHC box plot shows higher RNA5SP508 RNA expression in tumor versus normal tissue (log2 FC = +0.461, t-test p = .001).
This table shows molecular features associated with RNA5SP508 in patient tissues and cancer cell lines. In patient samples, RNA5SP508 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
